Table 1 Comparison of clinical characteristics between T-LGLL patients with or without PRCA
Patients with PRCA (7) | Patients without PRCA (21) | P | |
|---|---|---|---|
Gender | 1.000 | ||
Male | 3 (42.9) | 8 (38.1) | |
Female | 4 (57.1) | 13 (61.9) | |
Age | 0.668 | ||
Mean ± SD | 57.3 ± 10.2 | 55.4 ± 9.0 | |
LDH | 0.165 | ||
>250 U/L | 4 (57.1) | 5 (23.8) | |
<250 U/L | 3 (42.9) | 16 (76.2) | |
β2-MG (n = 25) | 0.030 | ||
>3.0 mg/L | 6 (85.7) | 6 (33.3) | |
<3.0 mg/L | 1 (14.3) | 12 (66.7) | |
Neutropenia, no.% | 6 (85.7) | 9 (42.9) | 0.084 |
Lymphocytosis, no.% | 4 (57.1) | 11 (52.4) | 1.000 |
LGL count in PB,×109/L | 0.295 | ||
Mean ± SD | 3.2 ± 2.1 | 2.9 ± 1.7 | |
Splenomegaly, no.% | 5 (71.4) | 5 (23.8) | 0.063 |
STAT3 mutation | 5 (71.4) | 1 (4.8) | 0.001 |